WO1994017855A1 - Electrotherapeutic apparatus - Google Patents

Electrotherapeutic apparatus Download PDF

Info

Publication number
WO1994017855A1
WO1994017855A1 PCT/GB1994/000211 GB9400211W WO9417855A1 WO 1994017855 A1 WO1994017855 A1 WO 1994017855A1 GB 9400211 W GB9400211 W GB 9400211W WO 9417855 A1 WO9417855 A1 WO 9417855A1
Authority
WO
WIPO (PCT)
Prior art keywords
electrodes
pain
stimulation
tse
nervous system
Prior art date
Application number
PCT/GB1994/000211
Other languages
French (fr)
Inventor
Alexander John Ranald Macdonald
Timothy William Coates
Original Assignee
Macdonald Alexander John Ranal
Timothy William Coates
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macdonald Alexander John Ranal, Timothy William Coates filed Critical Macdonald Alexander John Ranal
Priority to US08/500,843 priority Critical patent/US5776170A/en
Priority to GB9515702A priority patent/GB2290033B/en
Priority to AU59756/94A priority patent/AU5975694A/en
Publication of WO1994017855A1 publication Critical patent/WO1994017855A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014External stimulators, e.g. with patch electrodes
    • A61N1/36021External stimulators, e.g. with patch electrodes for treatment of pain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014External stimulators, e.g. with patch electrodes
    • A61N1/36017External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin

Abstract

An apparatus for producing analgesia through electrical stimulation is disclosed wherein the apparatus comprises two or more electrodes adapted to supply electrical signals to two or more locations on the surface of a body overlying the central nervous system. The apparatus further comprises signal generating means connectable to the electrodes which supply electrical pulses featuring rapid rising and falling phases at parameters of pulse width, frequence and amplitude such that analgesic effects tend to be stimulated in the central nervous system or its adnexa, while stimulating peripheral nerves that lie between the electrodes and the central nervous system to a lesser extent or not at all.

Description

ELECTROTHERAPEUTIC APPARATUS
This invention relates to the field of electrotherapy, and provides apparatus for a particular application of such therapy.
The nervous system is able to respond to an interrupted DC or alternating current, provided the repetition rates or frequencies do not exceed values that vary according to the particular properties of each class of nerve. Severe dull or aching pain is associated with the firing of un yelinated or C fibres (Class IV) . These fibres cannot follow a maintained frequency higher than about 2 Hz. In addition they have a high threshold and normally only respond to excessive mechanical or thermal stimulation that injures cells. Sharp pain is associated with the firing of Aδ (Class III) fibres. They cannot follow electrical stimulation rates higher than about 50-80 Hz. There is also a class of nerve fibres that may faithfully follow electrical stimulation at rates up to approximately 800 Hz; these are called Aβ or Class II fibres. The Class II receptors have a low threshold to any form of stimulation and respond to such innocuous events as movement or light touch. elzack and Wall (1965) and Wall (1986) describe how analgesia can be produced when the Class II or Aβ fibres are stimulated electrically at 100 Hz, a frequency that none of the other nerves can follow.
Wall (1986) produced these effects by applying the current through needles inserted into the patient's nerves. To avoid the inconvenience and possible complications of inserting needles into nerves, surface electrodes were later employed, leading to the term Transcutaneous (Electrical) Nerve Stimulation (TNS or TENS) .
Woolf (1989) has reviewed the use of these devices, and described their electrical parameters. The usual TENS machine develops a pulse, whose width can be varied from 50 500 μs, employing a current whose amplitude can be increased from 0 - 50 mA, and whose frequency is generally 80 or 100 Hz. The TENS pulse width (50-500 μs) is intended to be sufficiently long in duration to excite Aβ nerves to cause a painless tingling at low voltage.
In known TENS devices, the maximum current density and sensation tends to occur in tissues immediately underlying the electrodes, and only a proportion of the applied current reaches the deep tissues. Thus, when choosing a comfortable level of stimulation, the patient is first guided by sensations arising from peripheral nerve stimulation in tissues immediately below the electrodes. If the amplitude is increased to try and produce more current in the deep tissues, pain may be produced when there is sufficient voltage to recruit Aδ fibres. This tends to limit the amplitude of TENS that can be tolerated by a patient. Although tingling produced by the TENS method is usually painless and reasonably well accepted by patients, it tends to produce a rather short-lived, localised region of analgesia, as each electrode probably stimulates a few hundred Aβ fibres in the immediate vicinity of the electrodes. Accordingly, in patients where there may be several large areas of the body in pain, there is a need to improve the method to produce a more long-lasting and generalised form of analgesia.
In an attempt to fire more Aβ fibres, wire electrodes have been implanted in the spinal canal to stimulate the central nervous system itself, in particular the dorsal columns (tracts through which the Aβ fibres pass up and down the spinal chord) . This is called Dorsal Column Stimulation, and is reviewed by Krainick et al (1989) . The present technique employs small bare tips of otherwise insulated wires, probably stimulating a few thousand Aβ fibres. However, the implantation of the wires involves surgery and the risk of infection along the track of the wires.
In order to avoid the risks of implanting electrodes in direct contact with the central nervous system, US3835833 (Limoge) describes application to a patient's head of intermittent 4 ms blocks of high frequency current (166 KHz) , each block being repeated 100 times per second, designed to penetrate the brain from two surface electrodes. Breaking the signal up into these trains tends to excite peripheral nerves and Stinus et al (1990) have observed that such stimulation only raises pain thresholds when opiates have been administered.
Accordingly, the present invention provides an apparatus for producing electrical stimulation wherein the apparatus comprises two or more electrodes adapted to supply electrical signals to two or more locations on the surface of a body overlying the central nervous system, wherein the apparatus further comprises signal generating means connectable to the electrodes which supply electrical pulses having rapid rising and falling phases at parameters of pulse width, frequency and amplitude such that analgesic effects tend to be stimulated in the central nervous system while stimulating peripheral nerves that lie between the electrodes and the central nervous system to a lesser extent or not all.
Thus the present invention allows analgesic effects all over the body to be initiated in the central nervous system, in particular the spinal cord, preferably without requiring prior medication or causing any discomfort. We refer to this as Transcutaneous Spinal Electroanalgesia
(TSE) , and it depends on electrical signal being applied via surface electrodes to initiate changes in the central nervous system, for instance the spinal cord lying some 5 cms deep to the skin, without exciting the peripheral nerves in the intervening tissues.
In the context of the present invention, the term "central nervous system" should, except where the context demands otherwise, be interpreted to include the brain and spinal cord, together with their adnexa, ie other neural tissues that are classed as part of the peripheral nervous sytem, but are in close anatomical proximity to the central nervous system, eg the ganglia, autonomic or somatic, such as the dorsal root ganglia.
The approach we have adopted here accords with apparent stimulation of the spinal cord by summation. This may be explained as follows. The minimum current required to stimulate each class of nerve has been studied (Brinley 1974, pages 34-36) . This minimum value is called a threshold stimulus. To elicit a response in a nerve, the threshold electrical stimulus must be applied for a finite time; the weaker the current, the greater the time required for stimulation. If the strength of the stimulating current is below a minimum quantity, the current may flow indefinitely without exciting the nerve. On the other hand, a current lasting less than a minimum length of time will not stimulate, however great its amplitude. There are great differences, however, between the responsiveness of the various classes of nerves to periods of stimulation at various amplitudes.
For example, Li et al (1976, page 72, Fig. 4) have shown
(in a peripheral nerve of the cat) the minimum length of time required to stimulate Aβ fibres with a current of 0.2 mA is 6 μs; whereas at the same amplitude Aδ fibres and C fibres require periods of stimulation at least a hundred times as long in duration (i.e. in excess of 600 μs) .
When an electrical stimulus is subthreshold (i.e. too brief in duration and amplitude to cause a nerve to fire) , it still has an effect on the nerve that may make it more responsive to another stimulus. Thus, the phenomenon of summation occurs, when two or more subthreshold stimuli combine to cause excitation. Spatial summation may be described in the following way. Although the effects of subthreshold electrical stimulation of a nerve are at their greatest in the immediate vicinity of the electrode, changes also take place in adjacent regions. Thus simultaneous subthreshold stimulation in two or more loci are able to summate to produce excitation. Whether summation is the mechanism of action or not,
TSE avoids stimulating peripheral nerves, yet provides a signal that produces effects in the central nervous system, possibly by stimulating vesicles to release opioids such as metenkephalin or dynorphin. 1. The TSE Stimulator
One embodiment of the present invention employs a single pair of electrodes, typically having a size of 4 X 4 cm. Usually one electrode is placed on the skin of the mid-line of the back overlying one end of the portion of spinal cord that requires stimulation, while the second is placed at the other end. In "a similar manner, however, more than two electrodes could be arranged over the spinal cord.
We have also found that when electrodes are placed on either side of the neck, analgesic effects may be obtained in the cranium. We have also attached electrodes to the skin overlying the brain, and have obtained analgesic effects depending on various parameters of stimulation, but side effects such as flashes of light and a metallic taste are sometimes produced. Accordingly, the placement of the electrodes on regions overlying the spinal cord is preferred as this has not produced any known side effects.
Although in general electrodes are placed on the surface of a body, in some circumstances it may be desirable to implant the electrodes. This is generally not preferred due to the risk of infection associated with this procedure.
In order to stimulate the spinal cord without producing discomfort, we have studied the effects of a TSE stimulator designed to produce a pulses having both rapid rise and fall phases. This device has been used in the following experiments, described below with reference to the circuit diagram shown in Fig. 1. It features an output pulse which is variable in amplitude between approximately 450V or less and has a pulse width typically of lOμs or less, eg 1.5-4 μs. This pulse is repeated at intervals of approximately 4μs or more. The stimulator is designed to give pulses having rapid rise and fall phases, eg a substantially rectangular pulse wave, even at maximum amplitude when driving 4 x 4 cm stick-on skin electrodes. Both monopolar and bipolar pulses having rapid rise and fall phases can be applied to a patient via the electrodes.
This ability to control the shape of the output pulse even when driving a capacitive load together with the narrow pulse width used for stimulation constitutes the major differences between this TSE stimulator and conventional TENS-type stimulator machines. In the latter devices, the shape of the output wave is substantially dominated by the load impedence of the body, and the minimum TENS pulse width is typically 100 times longer than TSE. In addition, when applied at the normal TENS frequency of 100Hz the amplitude of the pulse produced by the TSE stimulator is higher than that of the conventional TENS machines i.e. typically 180V, but even up to IkV or more, compared to 35-50V. The narrow 1-10 μs TSE pulses can be delivered at higher frequencies than is possible with the broader TENS pulses (typically 50-500 μs) . Typically it is possible to use signals having a frequency up to about 250 kHz. We have made the unexpected discovery that the higher the frequency we deliver to the patient with TSE, the more rapid the onset of analgesia; for example frequencies in the region of 150KHz produce analgesia within 5-30 minutes, whereas 100 Hz takes 40-60 minutes. The analgesia obtained in this way indicates a novel mode of action, as the frequency and pulse width employed in TSE lie outside the limits of conventional nerve stimulation.
Referring to the circuit diagram in Fig. 1, gates Gl and G2 form an astable multivibrator whose mark-space ratio is determined by the diodes Dl and D2 and their associated components. VR2 controls the duration of the output pulse which drives the Darlington pair comprising transistor Ql and Q2. Q2 feeds a voltage step-up transformer the secondary of which is connected via rectifier diode D4 to a lμF DC charge storage capacitor. Since VR2 controls the energy supplied to the primary of the step-up transformer, it controls the transformer's output and thus the amplitude of the output pulse. The pulse train appearing at the output of the stimulator is determined by gates G3, G4, G5, G6 and the associated circuitry. Gates G3, G4 and the associated RC network comprise an astable multivibrator producing a square wave running at 100Hz. Gates G5 and G6 comprise a monostable multivibrator circuit whose pulse width can be set by variable resistor VR1 and whose output is triggered by the 100Hz input coming from the previously described astable circuit. The output at gate 6 therefore provides narrow pulses variable between approximately 4 and lOμs appearing at intervals of 10ms.
These pulses drive transistor Q3 which is an emitter follow buffer stage. This stage drives the output MOSFET device Q4. A lmH inductance is used as the emitter load for Q3 to preserve the shape of the output pulse driving Q4. Q4 is used to switch the high voltage to the electrodes. The lmH choke in parallel with the output preserves the fast rise and fall time of the pulse when driving capacitative loads. The diode D5 in parallel with the inductor restricts excursions during the falling phase of the pulse to approximately -0.7 V, giving a substantially monopolar pulse. In addition, the lmH choke in parallel with the output provides a failsafe mode of operation, in that should the output device Q4 go short circuit, thus applying the full charge to the skin electrodes, the choke will provide a short circuit at DC and very quickly pull the output low, thus protecting the patient. The main features of this stimulator circuit are that it provides a high voltage, that is up to approximately 450V, a narrow pulse width, around l-10μs, and that this pulse has short rise and fall times, so that even under adverse output conditions a narrow pulse with short rise and fall times is maintained. This is useful for the kind of stimulation which we believe to be effective in producing analgesia by means of a painless form of electrical stimulation applied to the surface of the body that nevertheless produces effects in the central nervous system. In addition, the device has a safe failure mode since the patient is protected against continuous voltage at the output.
The foregoing circuitry is of course only one example, and may be modified in many ways to achieve a similar, or modified, effect. For example, a pair of output transistors arranged to switch a positive and a negative
(with respect to ground) supply line respectively could, when driven appropriately, be made to produce mono and/or bipolar rectangular pulses of narrow width. While a pulse interval of 10 ms may be provided, giving a pulse frequency of about 100 Hz, the design may be modified to produce higher frequencies. Likewise, the pulse width can be varied in the region of 10. μs or less in the exemplified apparatus. Similarly the variable voltage output can be arranged to extend higher than 450V if desired.
In addition, the placement of a capacitor in series with one of the electrodes serves to isolate the patient from the possibility of direct current stimulation, which results from a build-up of voltage across the output inductor and can cause electrolytic lesions. This effect becomes more important at high frequencies, eg 150kHz and above. The series capacitor together with the load impedence presented by the patient form a differentiator circuit and a bipolar differential rectangular wave appears at the electrodes. Such an arrangement is very effective in producing analgesia, with the advantage that treatment time is reduced (eg to less than 5 minutes) as it is possible to use high frequency pulses. 2. Experimental
Surface electrodes were attached to the stimulator that produced a square wave pulse of 4-8 μs duration, at a rate of 100 pulses per second, at various amplitudes
(voltages) , to see whether the phenomenon of spatial summation could be produced in the spinal cord.
In the following description, the conventional notations for the spinal column will be used, namely: L1-L5 are the five lumbar vertebrae, T1-T12 are the twelve thoracic vertebrae, and C1-C7 are the seven cervical vertebrae; furthermore in adult man the spinal cord descends from the base of the brain in the cervical region and reaches only as far down the spine as T12, where it rapidly tapers to a point at the lower border of LI, there to give off a sheaf of roots of the lower spinal nerves called the cauda equina that descends further down the spinal canal. When two 4 x 4 cm electrodes were placed close together anywhere on the mid-line of the back over the spine from Tl downwards, a tingling sensation only was produced.
However, if the electrodes were separated by a distance of 10 cms or so the levels between Tl and T12 could be perceived and described by the trained observer at a lower threshold than the tingling. It was a continuous feeling of warmth and painless, light pressure. However, this sensation is so mild in intensity, that many patients distracted by their aches and pains are unable to perceive it. Nevertheless amongst those that report this sensation, the most striking observation about it is its continuity; the discrete sensations produced by each pulse are not detectable, as it is when tingling is present. This new feeling may be called 'spinal cord sensation1 as it is only obtained when the electrodes are placed in the immediate vicinity of the spinal cord itself. It could not be obtained anywhere else on the body. We tried but failed to obtain it by placing electrodes over the median nerve in the forearm or over the anterior trunk or over the length of the left 6th intercostal nerve. This feeling was not obtainable, when the electrodes were placed over the spine from L2 downwards. Here the electrodes lay not over the cord however, but the spinal nerve roots lying in the cauda equina. If the electrodes were placed between the levels of T1-T12 but a few cms from the mid-line of the back, the spinal cord sensation was still obtainable; but if one moved out a hand's breadth (say ca 11cm) laterally from the spine then the feeling was lost. When the electrodes were located over the spinal cord, amplitudes capable of producing the spinal cord sensation were always lower than those capable of producing tingling sensation provided the stimulation was continuous and had a fast rise and fall time. This will be seen from the following two experiments where the anode was placed at Tl, and the cathode at T12. In these examples the frequency was 100 Hz.
In the first experiment, TSE pulses that were near rectangular in shape and had both fast rise and fall times were investigated. The effects of continuous stimulation were compared with those engendered by intermittent 4ms trains of pulses with 6ms rest periods so that each train is repeated one hundred times a second. The amplitude was increased slowly to determine at what voltage spinal cord sensation and tingling could be perceived: it could only be perceived during continuous stimulation. As the pulse width increased in duration the thresholds of spinal cord sensation and tingling became closer. At 10 μs there was scarcely any difference between the two.
In the second experiment, a pulse of a different shape was employed a fast rise time was maintained. However, the near rectangular shape was not present and the fall time decayed exponentially. Again continuous stimulation was compared with intermittent. Spinal cord sensation was not observed with either.
First Experiment: TSE Pulse With Fast Rise and Fall Times. CONTINUOUS STIMULATION INTERRUPTED STIMULATION
Pulse Threshold Threshold Threshold Threshold width Spinal Tingling Spinal Tingling cord Sensation Cord Sensation Sensation Sensation μs V V V V
2 96 118 - 98
4 46 65 - 55
6 29 40 - 38
8 28 32 - 28
10 22 23 - 22
Second Experiment: non-TSE Pulse With Fast Rise and Exponential Fall Times.
CONTINUOUS STIMULATION INTERRUPTED STIMULATION
Pulse Spinal Tingling Spinal Tingling Width Cord Sensation cord sensation
Sensation Sensation μs V V V V
2 - 43 - 35
4 - 32 - 31
6 - 26 - 23
8 - 20 - 18
10 - 17 - 16 Increased spinal cord sensation when the distance between the electrodes was increased
We found very surprisingly that provided the electrode that comprised the cathode was placed below the anode, the amplitudes required to produce spinal cord sensation were reduced, the greater the separation between the electrodes. To support this observation, we tried to blind our study as much as possible.
Two pairs of electrodes were placed on the mid-line of the back: one pair was arranged with its electrodes on Tl and T12, while the other pair was arranged with its electrodes placed at various distances apart, but never as far apart as the first pair. Indeed the electrodes of the second pair were always placed between those of the first pair (i.e. between levels T3-T7) .
The cables from the first pair of electrodes were deliberately muddled up by the experimenter, and the subject tried first one cable and then the other in a blind fashion to see which cable (when inserted into the stimulator) produced the most spinal cord sensation.
Surprisingly, it was very difficult to locate the segmental level of the sensation once it was felt. However on all occasions, the electrodes separated from each other by being placed at Tl and T12 produced more sensation than the pair of electrodes placed closer together at a given amplitude.
Provided TSE is employed with the cathode being placed below the anode in regions that overlie the spinal cord, the further apart the electrodes are placed, the lower the amplitude is required to produce this unusual continuous spinal cord sensation. However, as expected, when the amplitude of TSE (at frequencies less than 800 Hz) is increased sufficiently to start exciting Aβ fibres to cause a tingling sensation, this is less likely to occur at any given voltage the further apart the electrodes are placed. For example when employing one pair of 4 x 4 cm electrodes disposed over the mid-line of the back, the following amplitudes were recorded at a pulse width of 4μs and a frequency of 100Hz;
Electrode size: 4 x 4 cm
Electrode Amplitude: volts location Spinal cord sensation Tingling sensation
Tl, T2 not obtainable 84 Tl, T6 76 96
Tl, T12 70 100
Effects of broadening the pulse width Then we investigated what happened if we broadened the pulse width. As one would expect the thresholds of both spinal cord sensation and tingling dropped as the pulse was broadened. On this occasion, we recorded not only spinal cord sensation, but also the pain thresholds of tingling. Electrode size: 4 x 4 cm
Electrode Pulse width Amplitude (volts) location (μs) Spinal Pain threshold cord tingling sensation sensation
Tl, T12 4 100 220
Tl, T12 8 60 110
Effects of treatment We then considered what would happen if spinal cord sensation was maintained for 10 minutes on a patient. He had a painful right knee for the past three weeks, associated with a tender medial ligament. An instrument called an algometer (that measures pressure exerted by the examiner on the patient's skin in kg/cm2) was used to measure the mechanical pain thresholds, not only on the injured right knee but also the unaffected side.
Stimulation parameters: Size of electrodes: 2 x 4 cm;
Location of electrodes: Tl, T12;
Time of stimulation: 10 minutes
Amplitude: 225 volts and Pulse width: 4 μs Resul ts :
Knee Mechanical pain threshold (kg/cm2) before stimulation after stimulation Right (injured) 1.1 3 Left (unaffected) 3.5 2
Thus within ten minutes treatment, the injured knee that had been 3.18 (3.5/1.1) times more tender than the unaffected side, became 0.66 (2/3) times less tender. Conclusion We may assess the beneficial effect as associated with well spaced electrodes over the spinal column, preferably no lower than T12, and for practical reasons it is usually difficult to attach an electrode to the body higher than Tl; but these effects may still be obtained, if the upper electrode(s) are attached to the cervical or cranial regions. The pulse width is likely to be in the range of l-10μs. The voltage need not be sufficient to cause tingling associated with Aβ fibre excitation; thus it may be subthreshold for the selected pulse width. Preferably, the voltage with be less than IkV.
At 600 Hz typically up to about 250V may be employed to produce analgesia at a 4 μs pulse width; but this voltage may need to be higher for a narrower pulse width, and could be lower for a broader width. At higher frequencies, unwanted heated effects begin to occur, so the voltage has to be decreased; for example, with a 1.5 μs pulse width and a frequency of 5KHz, 150V are sufficient, while at 150KHz a voltage of 25V was found to be effective.
The pulse shapes considered so far are monopolar, however bipolar pulses have been found to also produce analgesia. The latter may be useful in reducing electrolytic effects. As mentioned above, the electrolytic effects can be reduced by placing a capacitor in series with one of the electrodes. The electrodes may be separate and individually applied to the skin, but for convenience, particularly to enable the patient to use the apparatus without help, they may be incorporated into a harness which the patient can wear, and adjust so that the electrodes make proper contact with the skin overlying the desired spinal column regions. If required, the electrodes may be implanted in the body either in tissues near the spine or within the spinal canal itself. The Effects of TSE
Mechanical pain pressure thresholds may be obtained by a spring loaded probe (called an algometer) and are measured in kg/cm2 (Reeves et al, 1986) .
TSE stimulation tends to raise the mechanical pain pressure thresholds in tender regions of the body, whereas it may reduce the pain pressure thresholds in the previously non-tender regions. in the case of unilateral injuries, when the tenderness of the injured area on one side was compared with the same (uninjured) region on the other side, ratios of non-tender/tender region pain pressure thresholds tend to be reduced by TSE to unity (p< 0.001) . if a patient is in a good deal of pain in a particular region on one side of the body only, the tender or injured region has a low mechanical pain threshold, usually lkg/cm2 or less, whereas the threshold on the opposite (uninjured) side of the body is usually 2 kg/cm2 or more. Thus, if we take a ratio of the non-injured/injured mechanical pain thresholds, it will often be 2 or more.
Following 40 minutes or so TSE therapy, however, this ratio tends to be reduced to 1. At relatively low TSE frequencies, the mechanical pain threshold in the injured region rises, whereas the pain threshold in the non-injured regions falls. But at higher frequencies, the onset of analgesia is more rapid, and there is a tendency for the thresholds to rise in both regions: but the threshold in injured region rises at a faster rate than in the non- injured.
Studies of this kind, carried out on patients who only have a tender region on one side of the body has led to an unexpected discovery. Before treatment, sensitivity to light touch (measured with von Frey hairs (von Frey, 1896)), two point discrimination, warmth (measured by applying two equally warm steel rods on the body) , and pin- prick (measured with weighted needles (Chan et al, 1992)) is reduced in the tender myofascial region, as compared with the non-tender.
Following a 40 minute period of TSE, however, these differences tend to disappear. The mechanical threshold in the injured area is raised, while the thresholds to all other types of sensation fall to the levels found on the uninjured side.
Despite the fact that the electrodes are always located over the spinal cord, these changes occur wherever the tender region lies, be it in the foot, hip, back, wrist shoulder or head or all of these regions simultaneously.
These observations suggest that TSE produces pain relief without introducing numbness in the manner of local anaesthesia. TSE tends to have the opposite effect of local anaesthesia and following this therapy, although the tenderness has been reduced, the patient's perception of pin-prick, warmth, light touch and ability to discriminate between two points tend to be heightened in the injured area. When pain relief occurs as a result of TSE, one may observe a temporary but generalised vasodilatation (a warming up of the skin caused by relaxation of vascular tone usually brought about by a reduction in sympathetic activity that normally accompanies pain relief) . Apart from these findings, we have not observed any other changes. No numbness or loss of motor power occurs. There are no changes in reflexes, pulse rate or blood pressure. In common with the TENS and dorsal column stimulation, that has been used for the past two decades, there appear to be no known side effects from this type of stimulation. Clinical Studies
In all the clinical studies detailed below TSE was carried out with two electrodes placed over the spinal cord. In a study of 23 patients suffering from a number of painful, chronic, subacute and acute conditions, TSE produced an average of 70% pain relief for an average of 50 hours following the first treatment of no more than 45 minutes stimulation. These results are set out in table 1 on pages 22 and 23. Here a 4μs pulse width was employed at a frequency of 100 Hz. The voltage was increased in each case to try and produce a spinal cord sensation at approximately 180V. In those patients who were unable to perceive the spinal cord sensation, the voltage was increased until they just began to experience a tingling sensation, which experiments have shown to be more than sufficient to cause spinal cord sensation in those who can perceive it.
The effects of repeated TSE therapy were then investigated in a further group of 50 consecutive chronic pain sufferers (see table 2) .
When the results for the first 100 conscutive patients were analysed, 63% of these patients, who had painful conditions of relatively recent origin (on average 2.6 years) required 3-5 treatments to produce a 60% or more subjective relief of pain during the treatment period. These patients appeared to derive a cumulative effect, ie it was found that when each treatment is repeated, the duration of relief provided tended to be longer. However, 30% of these patients, who had more severe, long lasting conditions (on average of 12 years duration) did not benefit from this accumulative effect. To remain comfortable they required TSE to be repeated daily or every other day. However, as the location of the TSE electrodes are standardised, it is not difficult for relatives or carers or even the patient himself to continue TSE at home.
Surprisingly, if patients with conditions as neuro- or psychogenic pains are excluded, only 7% of these severely affected patients did not obtain pain relief from TSE. This very low figure compares with the 60% failure rate of TENS. Those patients who invariably fail to derive any form of relief from TSE tend to have very severe pain associated with mechanical spine disorders. These patients are often bed-bound and are usually awaiting orthopaedic or neurosurgical procedures. Often the skin has developed a hyperaesthesia (sensitivity to light touch) over large regions of the body. Other conditions that are associated with hyperaesthesia such as post-herpetic neuralgia also do not respond well. However, we have found that reversing the polarity of the electrodes appears to give some short term relief of hyperaesthesia.
The patients whose conditions responded well to treatment were those who are reasonably mobile and suffer more common pains that are not associated with pressure on nerve roots. Chronic myofascial or osteoarthritic pains in almost every region of the body such as knees, elbows or shoulders, also tend to do well with the electrodes placed at Tl and T12. For pains arising in the head itself, however, such as chronic sinusitis, jaw or dental pain, we found that the most effective location of electrodes were either side of the neck in the vicinity of the cervical segments of the cervical cord.
TSE has provided pain relief to those patients who have fibromyalgia, ME or post-viral disorders where they have pains in many regions simultaneously. However their feelings of fatigue were found to remain.
Chronic post-injury or post-operative pains tend to do well. But acute or active arthritic pains such as rheumatoid arthritis also may respond but to a much lesser degree. In all these cases, regardless of the site of pain or the number of such sites, the electrodes are merely placed over the spinal cord. Controlled Clinical Trial.
A controlled clinical trial of TSE has been carried out. It received approval from the United Bristol Hospital Trust Research Ethics Committee. It was a randomised double- blind, cross-over study of the pain relieving effects of TSE versus TENS in patients suffering chronic pain of musculoskeletal origin.
Eight consecutive 'stably unwell' adult patients, who had intact nervous systems and a duration of daily musculoskeletal noninceptive (as opposed to neurogenic or psychogenic) pain for a year or more were studied. Their average age was 55 years, and the average duration of continuous pain was 12,4 years; their average physical disability index (Fairbank et al (1980)) or incapacity was 52.8 percent (0%, no incapacity; 100%, total incapacity).
Provided that various exclusion criteria did not apply, the patients were randomly assigned to one of two groups - TSE or TENS, in a double-blind cross-over manner, so that on one occasion a patient might receive TENS and on the next TSE, or vice versa.
Special apparatus was constructed, so that TSE or TENS could be applied in such a way that only an external trial coordinator knew which treatment was being applied on any particular occasion. In both cases the stimulation was supplied to electrodes placed over the skin overlying the spinal cord.
Neither the practitioner nor the patient was aware of which type of treatment was actually in use on any occasion. In this way the patients acted as their own controls, and received both types of treatment in a random, 'double-blind1 order.
As pain is so difficult to quantify, the following six measures of efficacy of each type of treatment were studied. Short Form McGill questionnaires (Melzack, 1987) were used to indicate the severity of pain before and after each treatment. A pain reduction score (0, no reduction: 100, complete reduction) and the number of hours this lasted after each type of treatment gave an important indication of the success or otherwise of each form of therapy. Changes in physical signs (including measurements of tenderness by algometry) and their severity, and the number and size of tender regions gave further indication of the effects of each type of treatment.
For the purpose of this clinical trial, each patient needed to attend for two hour periods at four weekly intervals.
Statistical analysis was performed by the non- parametric Wilcoxon rank sum test to compare the results obtained by TSE with TENS.
Four out of the six measures of efficacy revealed the probability that these two treatments were equally effective was less than 0.5% (ie p< 0.005). In the remaining two measures of efficacy the probability was less than 1% (ie p< 0.01) .
When all the measures of efficacy were combined the effects of TSE was shown to be significantly superior to TENS (p< 0.005) .
References
Brinley FJ (1974) , Excitation and conduction in nerve fibres. In: Medical Physiology (vol 1). Ed: Mountcastle VB. 13th Ed. The CV Mosby Co, pp 34-76. Chan AW, MacFarlane IA, Bowsher D, Campbell JA (1992), Weighted needle pin prick thresholds, a simple test of sensory function in diabetic peripheral neuropathy, J. Neurol. Neurosurg. Psychiat. 55, 56-59. Fairbank JCT, Couper-Mboat J, Davies JB and O'Brien JP (1980) , The Oswestry low back pain disability questionnaire, J. Physiotherapy 66, 271-273.
Krainick j-u, Thoden U (1989) , Spinal cord stimulation. In: The Textbook of Pain. Eds: Wall PD, Melzack R. 2nd Ed. Churchill Livingstone, pp 920-924.
Li CL, Bak A (1976) , Excitability characteristics of the A- and C- fibres in a peripheral nerve. Exp. Neurol. 50, 67- 79. Melzack R, Wall PD (1965), Pain mechanisms: a new theory. Science (150) 971-979. Melzack R (1987) , The short-form McGill Questionnaire, Pain 30, 191-197.
Reeves JL, Jaeger B and Graff-Radford SB (1986), Reliability of the pressure algometer as a measure of myofascial trigger point sensitivity, Pain 24, 313-321.
Stinus L, Auriacombe M, Tignol J, Limoge A, Le Moal M
(1990) , Transcranial electrical stimulation with high frequency intermittent current (Limoge's) potentiates opiate-induced analgesia: blind studies. Pain 42, 351-363. von Frey M (1896) , Untersuchungen uber die Sinnesfunctionen der Menschlchen haut erste abhandlung:druckempfindung und schmerz, Abhandlung der Sachsischen Akademie der Wissenschaften 23, 169-266.
Wall PD (1986) , The discovery of Transcutaneous Electrical Nerve stimulation. Journal of Orthopaedic Medicine 3, 26- 28.
Woolf CJ (1989), Segmental afferent fibre-induced analgesia: transcutaneous electrical nerve stimulation
(TENS) and vibration. In: The Textbook of Pain. Eds:
Wall, PD, Melzack R. 2nd Ed. Churchill Livingstone, pp 884- 896.
TABLE 1
Figure imgf000024_0002
Figure imgf000024_0001
No Sex Severity (0 nil- Duration Diagnosis % Relief (0 Duration of 10 agony (months) nil - 100 relief (hrs) total
15 F Aged 92: unable 9 Cervical Better 120 to quantify pain spondylitis numerically - described it as 'nasty' .
16 M 4 1 2° Ca spine 100 96
17 F 6 5 L5/S1 PID 50 120
18 F 2 12 Achilles tendonitis 80 72
19 M 8 0.001 Ischaemic pain in 90 NFP the calves - running while unfit
20 M 10 1 Collapse of 90 9 vertebral body c steroid therapy
21 M 2 120 Cervical 80 24 spondylitis
22 F 3 3 Shoulder pain 100 72
23 F 8 0.03 Fractured humerus 90 48
Average 56 71 53
Key: NFP no further pain; RA rhematoid arthritis; c associated with; 2° secondary carcinomatous deposits.
TABLE 2
The number of TSE treatments required to produce a successful outcome in the next 50 consecutive patients.
Key: c means associated with
OA means osteoarthritis
RTA road traffic accident
Success means pain relief at 60% or more (0, no relief;
100, complete relief)
NO Condition years number of contd duration treatments treat¬ required ment for long reqd term success
24 Tennis Elbow .2 3
25 Low back pain .25 3
26 Knee pains 1.5 5
27 Ovarian carcinoma 1.25 daily
28 Hip pain .75 5
29 Osteoporotic .5 daily collapse of vertebra c steroid therapy
30 OA cervical spine 12.0 4 and wrists
31 Post-viral fatigue 3.0 12 & post-operative - cardiac bypass pain
32 Shoulder pain .5 3
33 Post-operative 4.25 2 pain
(cholecystectomy) and a fall fracturing ribs
34 Rheumatoid .75 3 arthritis wrist and hands
35 Post-operative eye 5.25 10 pain c correction of squint & drug addiction Posterior thoracic 8.0 7 pain & anxiety depression
Leg pains 4.5 4 following episode of Guillain-Barre syndrome
Neck pains c 1.5 5 osteoporotic collapse of Tl
Generalised pains 12.0 5 c sarcoid
Generalised pains 10.0 daily c Parkinson's disease
Neck and low back 5.0 daily pain c 3 prolapsed disc injuries
OA neck and lumbar 11.0 8 spine
Leg pains & 15.0 alter¬ headache c anxiety nate days
Careino atous 2.0 daily deposits in spine
Elbow and shoulder .25 2 pain
Dysmenorrhoea 4.0 once a month
Cervical 10.0 5 spondylosis
Severe generalised 0.75 3 pains following a fall - compensation sought
Hip pain c lumbar 4.5 once a spine degeneration month
Heel pain 2.0 Once a week
Post-operative 0.5 3 pain following knee replacement Neck pain 1.5 3 following Cloward's fusion
Generalised joint 0.01 3 pains
Migrainous 10.0 Twice neuralgia daily during episode s
L4/5 disc 0.025 failed requiring surgery
Posterior thoracic 3.25 3 pain c OA cervical spine
C5/6 disc requires daily surgery
L4/5, L5/S1 disc 5.5 daily requires surgery, compensation sought
Athlete with back 0.5 4 and leg pains
Heel Pain 2.0 5
Post-viral fatigue 3.0 twice a c generalised pain week
Osteoporotic 2.5 4 collapse of T3
Hip pain following 4.5 5 a fall from scaffolding
Polymyalgia 5.5 daily rheumatica
Throat pain c 2.5 daily radiotherapy of larynx & morphine addiction
Cervical 12.0 once a spondylosis week following RTA
Post-herpetic 1.0 failed neuralgia Pain in posterior 0.5 2 thoracic region
Pain in shoulder 0.25 4 following a fall
OA knees and once a cervical spine week
Migraine 12.0 daily
OA neck c arm pain 25.0 once a week
Trigeminal 0.5 1 neuralgia

Claims

CLAIMS:
1. Apparatus for producing analgesia through electrical stimulation wherein the apparatus comprises two or more electrodes adapted to supply electrical signals to two or more locations on the surface of a body overlying the central nervous system, wherein the apparatus further comprises signal generating means connectable to the electrodes which supply electrical pulses having rapid rising and falling phases at parameters of pulse width, frequency and amplitude such that analgesic effects tend to be stimulated in the central nervous system while stimulating peripheral nerves that lie between the electrodes and the central nervous system to a lesser extent or not all.
2. The apparatus according to claim 1 wherein the analgesic effects are produced in the spinal cord.
3. The apparatus according to claim 1 or claim 2 wherein the electrodes are applied to the body overlying the spinal cord on or between the Tl and T12 vertebrae.
4. The apparatus according to any one of the preceding claims wherein the electrodes are separated by a distance of about 10cm or more.
5. The apparatus according to any one of the preceding claims wherein the means provides a series of pulses lOμs or less.
6. The apparatus according to claim 5 wherein the pulse width is between 1.5 to 4μs.
7. The apparatus according to any one of the preceding claims wherein the pulses are separated by a duration of about 4μs or more.
8. The apparatus according to any one of the preceding claims wherein the pulses have a frequency between about 100Hz and 250KHZ.
9. The apparatus according to any one of the preceding claims wherein the pulses have an amplitude of about IkV or less.
10. The apparatus according to claim 9 wherein the amplitude of the signal is less than about 250V.
11. Apparatus according to any one of the preceding claims for use in a method of treatment.
PCT/GB1994/000211 1993-02-05 1994-02-04 Electrotherapeutic apparatus WO1994017855A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US08/500,843 US5776170A (en) 1993-02-05 1994-02-04 Electrotherapeutic apparatus
GB9515702A GB2290033B (en) 1993-02-05 1994-02-04 Electrotherapeutic apparatus
AU59756/94A AU5975694A (en) 1993-02-05 1994-02-04 Electrotherapeutic apparatus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9302335.6 1993-02-05
GB939302335A GB9302335D0 (en) 1993-02-05 1993-02-05 Electrotherapeutic apparatus

Publications (1)

Publication Number Publication Date
WO1994017855A1 true WO1994017855A1 (en) 1994-08-18

Family

ID=10729950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1994/000211 WO1994017855A1 (en) 1993-02-05 1994-02-04 Electrotherapeutic apparatus

Country Status (4)

Country Link
US (1) US5776170A (en)
AU (1) AU5975694A (en)
GB (2) GB9302335D0 (en)
WO (1) WO1994017855A1 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0962234A1 (en) * 1998-06-05 1999-12-08 Pierenkemper GmbH Electrical stimulator for transcutaneous stimulation of nerves and muscles
EP0996482A1 (en) * 1997-07-16 2000-05-03 Impulse Dynamics (Israel) Ltd. Smooth muscle controller
EP1007148A1 (en) * 1997-03-10 2000-06-14 Medtronic, Inc. Technique for adjusting the locus of excitation of electrically excitable tissue
GB2414410A (en) * 2004-05-24 2005-11-30 Bioinduction Ltd Electro-analgesia device applying via body electrodes a biphasic signal having a particular inter-pulse spacing
US7006871B1 (en) 1997-07-16 2006-02-28 Metacure N.V. Blood glucose level control
US7930037B2 (en) 2003-09-30 2011-04-19 Medtronic, Inc. Field steerable electrical stimulation paddle, lead system, and medical device incorporating the same
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
US8958872B2 (en) 1996-01-08 2015-02-17 Impulse Dynamics, N.V. Electrical muscle controller
US8977353B2 (en) 2004-03-10 2015-03-10 Impulse Dynamics Nv Protein activity modification
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US9289618B1 (en) 1996-01-08 2016-03-22 Impulse Dynamics Nv Electrical muscle controller
US9713723B2 (en) 1996-01-11 2017-07-25 Impulse Dynamics Nv Signal delivery through the right ventricular septum
US9802041B2 (en) 2014-06-02 2017-10-31 Cala Health, Inc. Systems for peripheral nerve stimulation to treat tremor
US9931503B2 (en) 2003-03-10 2018-04-03 Impulse Dynamics Nv Protein activity modification
US10625074B2 (en) 2013-01-21 2020-04-21 Cala Health, Inc. Devices and methods for controlling tremor
US10765856B2 (en) 2015-06-10 2020-09-08 Cala Health, Inc. Systems and methods for peripheral nerve stimulation to treat tremor with detachable therapy and monitoring units
US10792495B2 (en) 2016-12-01 2020-10-06 Thimble Bioelectronics, Inc. Neuromodulation device and method for use
US10814130B2 (en) 2016-07-08 2020-10-27 Cala Health, Inc. Dry electrodes for transcutaneous nerve stimulation
US11331480B2 (en) 2017-04-03 2022-05-17 Cala Health, Inc. Systems, methods and devices for peripheral neuromodulation for treating diseases related to overactive bladder
US11344722B2 (en) 2016-01-21 2022-05-31 Cala Health, Inc. Systems, methods and devices for peripheral neuromodulation for treating diseases related to overactive bladder
US11439815B2 (en) 2003-03-10 2022-09-13 Impulse Dynamics Nv Protein activity modification
US11596785B2 (en) 2015-09-23 2023-03-07 Cala Health, Inc. Systems and methods for peripheral nerve stimulation in the finger or hand to treat hand tremors
US11779768B2 (en) 2004-03-10 2023-10-10 Impulse Dynamics Nv Protein activity modification
US11857778B2 (en) 2018-01-17 2024-01-02 Cala Health, Inc. Systems and methods for treating inflammatory bowel disease through peripheral nerve stimulation
US11890468B1 (en) 2019-10-03 2024-02-06 Cala Health, Inc. Neurostimulation systems with event pattern detection and classification

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6233488B1 (en) * 1999-06-25 2001-05-15 Carl A. Hess Spinal cord stimulation as a treatment for addiction to nicotine and other chemical substances
US6567702B1 (en) 1999-10-15 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University Eliciting analgesia by transcranial electrical stimulation
US6871099B1 (en) * 2000-08-18 2005-03-22 Advanced Bionics Corporation Fully implantable microstimulator for spinal cord stimulation as a therapy for chronic pain
US6882884B1 (en) 2000-10-13 2005-04-19 Soundskin, L.L.C. Process for the stimulation of production of extracellular dermal proteins in human tissue
EP1330287B1 (en) * 2000-10-26 2009-07-29 Medtronic, Inc. Apparatus to minimize the effects of a cardiac insult
US6618625B2 (en) * 2000-11-29 2003-09-09 Leon M. Silverstone Method and apparatus for treatment of viral diseases
US6757564B2 (en) * 2001-09-06 2004-06-29 D'alerta Mario Medical system using biomolecular treatment
US7127296B2 (en) * 2001-11-02 2006-10-24 Advanced Bionics Corporation Method for increasing the therapeutic ratio/usage range in a neurostimulator
AU2003210752A1 (en) * 2002-02-01 2003-09-02 The Cleveland Clinic Foundation Modulation of the pain circuitry to affect chronic pain
US6904322B2 (en) 2002-02-15 2005-06-07 Kalaco Scientific, Inc. Transcranial electrostimulation apparatus and method
WO2003095018A2 (en) * 2002-05-09 2003-11-20 Daemen College Electrical stimulation unit and waterbath system
US7657482B1 (en) * 2002-07-15 2010-02-02 Paymentech, L.P. System and apparatus for transaction fraud processing
EP1523368A1 (en) * 2002-07-17 2005-04-20 Remedi (UK) Limited Apparatus for the application of electrical pulses to the human body
US20050102006A1 (en) * 2003-09-25 2005-05-12 Whitehurst Todd K. Skull-mounted electrical stimulation system
US20050137652A1 (en) * 2003-12-19 2005-06-23 The Board of Regents of the University of Texas at Dallas System and method for interfacing cellular matter with a machine
US20090198293A1 (en) * 2003-12-19 2009-08-06 Lawrence Cauller Microtransponder Array for Implant
US7346382B2 (en) 2004-07-07 2008-03-18 The Cleveland Clinic Foundation Brain stimulation models, systems, devices, and methods
US7711432B2 (en) 2004-07-26 2010-05-04 Advanced Neuromodulation Systems, Inc. Stimulation system and method for treating a neurological disorder
US20060052856A1 (en) 2004-09-08 2006-03-09 Kim Daniel H Stimulation components
US9205261B2 (en) 2004-09-08 2015-12-08 The Board Of Trustees Of The Leland Stanford Junior University Neurostimulation methods and systems
US20120277839A1 (en) 2004-09-08 2012-11-01 Kramer Jeffery M Selective stimulation to modulate the sympathetic nervous system
US20060069436A1 (en) * 2004-09-30 2006-03-30 Depuy Spine, Inc. Trial disk implant
US8788044B2 (en) 2005-01-21 2014-07-22 Michael Sasha John Systems and methods for tissue stimulation in medical treatment
US20070073354A1 (en) 2005-09-26 2007-03-29 Knudson Mark B Neural blocking therapy
US20110034782A1 (en) * 2005-11-30 2011-02-10 Fujikin Corporation Apparatus for body surface stimulation treatment, program for body surface stimulation treatment, and computer-readable recording medium having recorded the same
US8892200B2 (en) 2006-06-19 2014-11-18 Highland Instruments, Inc. Systems and methods for stimulating tissue using focused energy
AU2007261108A1 (en) 2006-06-19 2007-12-27 Highland Instruments, Inc. Apparatus and method for stimulation of biological tissue
US8718758B2 (en) 2006-06-19 2014-05-06 Highland Instruments, Inc. Interface apparatus for stimulation of biological tissue
US9913976B2 (en) 2006-06-19 2018-03-13 Highland Instruments, Inc. Systems and methods for stimulating and monitoring biological tissue
JP5414531B2 (en) * 2006-12-06 2014-02-12 スパイナル・モデュレーション・インコーポレイテッド Delivery device and systems and methods for stimulating neural tissue at multiple spinal levels
US9314618B2 (en) * 2006-12-06 2016-04-19 Spinal Modulation, Inc. Implantable flexible circuit leads and methods of use
WO2008070808A2 (en) 2006-12-06 2008-06-12 Spinal Modulation, Inc. Expandable stimulation leads and methods of use
AU2008210504B2 (en) 2007-01-29 2012-07-26 Spinal Modulation, Inc. Sutureless lead retention features
US8121696B2 (en) * 2007-02-02 2012-02-21 Rommel P. Vallero Topical analgesia using electrical and vibration stimuli
US8224453B2 (en) * 2007-03-15 2012-07-17 Advanced Neuromodulation Systems, Inc. Spinal cord stimulation to treat pain
GB0709834D0 (en) 2007-05-22 2007-07-04 Gillbe Ivor S Array stimulator
US7630771B2 (en) * 2007-06-25 2009-12-08 Microtransponder, Inc. Grooved electrode and wireless microtransponder system
DE102007034065B4 (en) * 2007-07-20 2012-07-12 Prontomed Gmbh Pain therapy device
MX2010002912A (en) 2007-09-18 2010-05-19 Giuseppe Marineo Apparatus and method for quick pain suppression.
US20090204173A1 (en) 2007-11-05 2009-08-13 Zi-Ping Fang Multi-Frequency Neural Treatments and Associated Systems and Methods
WO2009070697A2 (en) * 2007-11-26 2009-06-04 Micro Transponder Inc. Implantable transponder systems and methods
US8457757B2 (en) 2007-11-26 2013-06-04 Micro Transponder, Inc. Implantable transponder systems and methods
US9089707B2 (en) * 2008-07-02 2015-07-28 The Board Of Regents, The University Of Texas System Systems, methods and devices for paired plasticity
DE112008003192T5 (en) * 2007-11-26 2010-10-07 Micro-Transponder, Inc., Dallas Transmission coils Architecture
KR200445363Y1 (en) 2007-12-31 2009-07-23 (주)아이티시 Surgical apparatus
US9220889B2 (en) 2008-02-11 2015-12-29 Intelect Medical, Inc. Directional electrode devices with locating features
US8019440B2 (en) 2008-02-12 2011-09-13 Intelect Medical, Inc. Directional lead assembly
US20090275996A1 (en) * 2008-04-30 2009-11-05 Medtronic, Inc. Techniques for placing medical leads for electrical stimulation of nerve tissue
US7890182B2 (en) 2008-05-15 2011-02-15 Boston Scientific Neuromodulation Corporation Current steering for an implantable stimulator device involving fractionalized stimulation pulses
US9272153B2 (en) 2008-05-15 2016-03-01 Boston Scientific Neuromodulation Corporation VOA generation system and method using a fiber specific analysis
EP3202457B1 (en) 2008-10-27 2020-05-27 Spinal Modulation Inc. Selective stimulation systems and signal parameters for medical conditions
US8498698B2 (en) 2008-10-31 2013-07-30 Medtronic, Inc. Isolation of sensing and stimulation circuitry
EP2367596A1 (en) * 2008-10-31 2011-09-28 Medtronic, Inc. Shunt-current reduction housing for an implantable therapy system
US9775987B2 (en) 2008-10-31 2017-10-03 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US8260412B2 (en) 2008-10-31 2012-09-04 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US8452394B2 (en) 2008-10-31 2013-05-28 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US9597505B2 (en) * 2008-10-31 2017-03-21 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US9192769B2 (en) * 2008-10-31 2015-11-24 Medtronic, Inc. Shunt-current reduction techniques for an implantable therapy system
WO2010051500A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. Therapy system including cardiac rhythm therapy and neurostimulation capabilities
US8249708B2 (en) * 2008-10-31 2012-08-21 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US8688210B2 (en) * 2008-10-31 2014-04-01 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US8611996B2 (en) 2008-10-31 2013-12-17 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US8774918B2 (en) * 2008-10-31 2014-07-08 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US8560060B2 (en) 2008-10-31 2013-10-15 Medtronic, Inc. Isolation of sensing and stimulation circuitry
US8005539B2 (en) * 2008-10-31 2011-08-23 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US8532779B2 (en) * 2008-10-31 2013-09-10 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US8255057B2 (en) * 2009-01-29 2012-08-28 Nevro Corporation Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US9327121B2 (en) 2011-09-08 2016-05-03 Nevro Corporation Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
WO2010068797A1 (en) * 2008-12-10 2010-06-17 Waverx, Inc. Devices, systems and methods for preventing and treating sensation loss
AU2010229985B2 (en) * 2009-03-24 2015-09-17 Spinal Modulation, Inc. Pain management with stimulation subthreshold to paresthesia
DE202010018338U1 (en) 2009-04-22 2015-10-12 Nevro Corporation Spinal cord modulation system for the relief of chronic pain
EP2756864B1 (en) 2009-04-22 2023-03-15 Nevro Corporation Spinal cord modulation systems for inducing paresthetic and anesthetic effects
US9259569B2 (en) * 2009-05-15 2016-02-16 Daniel M. Brounstein Methods, systems and devices for neuromodulating spinal anatomy
US8498710B2 (en) 2009-07-28 2013-07-30 Nevro Corporation Linked area parameter adjustment for spinal cord stimulation and associated systems and methods
JP5734295B2 (en) 2009-08-27 2015-06-17 ザ クリーブランド クリニック ファウンデーション System and method for estimating a site of tissue activity
BR112012001910A2 (en) 2009-09-21 2019-09-24 Medtronic Inc waveforms for electrical stimulation therapy
WO2011068997A1 (en) 2009-12-02 2011-06-09 The Cleveland Clinic Foundation Reversing cognitive-motor impairments in patients having a neuro-degenerative disease using a computational modeling approach to deep brain stimulation programming
EP2568904B1 (en) 2010-05-10 2019-10-02 Spinal Modulation Inc. Device for reducing migration
JP5830090B2 (en) 2010-06-14 2015-12-09 ボストン サイエンティフィック ニューロモデュレイション コーポレイション Programming interface for spinal nerve regulation
US20140148726A1 (en) 2010-10-21 2014-05-29 Timothy Andrew WAGNER Methods for detecting a condition
WO2012075198A2 (en) 2010-11-30 2012-06-07 Nevro Corporation Extended pain relief via high frequency spinal cord modulation, and associated systems and methods
AU2012212150B2 (en) 2011-02-02 2016-09-29 Spinal Modulation, Inc Devices, systems and methods for the targeted treatment of movement disorders
JP2014513622A (en) 2011-03-29 2014-06-05 ボストン サイエンティフィック ニューロモデュレイション コーポレイション Communication interface for therapeutic stimulus delivery system
WO2012155185A1 (en) 2011-05-13 2012-11-22 National Ict Australia Ltd Method and apparatus for measurement of neural response
CN103648583B (en) 2011-05-13 2016-01-20 萨鲁达医疗有限公司 For measuring method and the instrument of nerves reaction-A
US9872990B2 (en) 2011-05-13 2018-01-23 Saluda Medical Pty Limited Method and apparatus for application of a neural stimulus
US9974455B2 (en) 2011-05-13 2018-05-22 Saluda Medical Pty Ltd. Method and apparatus for estimating neural recruitment
WO2012155184A1 (en) 2011-05-13 2012-11-22 National Ict Australia Ltd Method and apparatus for measurement of neural response - c
US9592389B2 (en) 2011-05-27 2017-03-14 Boston Scientific Neuromodulation Corporation Visualization of relevant stimulation leadwire electrodes relative to selected stimulation information
AU2012294364A1 (en) 2011-08-09 2014-03-20 Boston Scientific Neuromodulation Corporation Remote control for blind clinical trials of electrical stimulation
US8594783B2 (en) 2011-08-24 2013-11-26 Highland Instruments, Inc. Systems and methods for stimulating cellular function in tissue
WO2013111137A2 (en) 2012-01-26 2013-08-01 Rainbow Medical Ltd. Wireless neurqstimulatqrs
US8676331B2 (en) 2012-04-02 2014-03-18 Nevro Corporation Devices for controlling spinal cord modulation for inhibiting pain, and associated systems and methods, including controllers for automated parameter selection
US9833614B1 (en) 2012-06-22 2017-12-05 Nevro Corp. Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods
EP2879757B1 (en) 2012-08-04 2019-06-26 Boston Scientific Neuromodulation Corporation Systems and methods for storing and transferring registration, atlas, and lead information between medical devices
EP2891091B1 (en) 2012-08-28 2018-01-31 Boston Scientific Neuromodulation Corporation Capture and visualization of clinical effects data in relation to a lead and/or locus of stimulation
US9792412B2 (en) 2012-11-01 2017-10-17 Boston Scientific Neuromodulation Corporation Systems and methods for VOA model generation and use
AU2013344311B2 (en) 2012-11-06 2017-11-30 Saluda Medical Pty Ltd Method and system for controlling electrical conditions of tissue
US9861812B2 (en) 2012-12-06 2018-01-09 Blue Wind Medical Ltd. Delivery of implantable neurostimulators
US9895539B1 (en) 2013-06-10 2018-02-20 Nevro Corp. Methods and systems for disease treatment using electrical stimulation
US9956408B2 (en) 2013-10-09 2018-05-01 Gimer Medical Co. Ltd. Method for reducing spasticity and non-transitory computer-readable medium thereof
US9526889B2 (en) * 2013-10-09 2016-12-27 GiMer Medical Co., Ltd. Electromagnetic stimulation device for changing nerve threshold
US10086197B2 (en) 2013-10-09 2018-10-02 GiMer Medical Co., Ltd. Method for reducing overactive bladder syndrome and computer-readable medium thereof
US10183165B2 (en) 2013-10-09 2019-01-22 GiMer Medical Co., Ltd. Method of reducing renal hypertension and computer-readable medium
US10149978B1 (en) 2013-11-07 2018-12-11 Nevro Corp. Spinal cord modulation for inhibiting pain via short pulse width waveforms, and associated systems and methods
US11172864B2 (en) 2013-11-15 2021-11-16 Closed Loop Medical Pty Ltd Monitoring brain neural potentials
EP3071100B1 (en) 2013-11-22 2024-01-03 Saluda Medical Pty Limited Method and device for detecting a neural response in a neural measurement
US10368762B2 (en) 2014-05-05 2019-08-06 Saluda Medical Pty Ltd. Neural measurement
US9959388B2 (en) 2014-07-24 2018-05-01 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for providing electrical stimulation therapy feedback
ES2873255T3 (en) 2014-07-25 2021-11-03 Saluda Medical Pty Ltd Neurological stimulation dosage
US10272247B2 (en) 2014-07-30 2019-04-30 Boston Scientific Neuromodulation Corporation Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming
US10265528B2 (en) 2014-07-30 2019-04-23 Boston Scientific Neuromodulation Corporation Systems and methods for electrical stimulation-related patient population volume analysis and use
EP3204112A1 (en) 2014-10-07 2017-08-16 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters
USD759803S1 (en) 2014-10-28 2016-06-21 Highland Instruments, Inc. Adjustable headpiece with anatomical markers
US9597507B2 (en) 2014-10-31 2017-03-21 Medtronic, Inc. Paired stimulation pulses based on sensed compound action potential
AU2015349614B2 (en) 2014-11-17 2020-10-22 Saluda Medical Pty Ltd Method and device for detecting a neural response in neural measurements
WO2016090420A1 (en) 2014-12-11 2016-06-16 Saluda Medical Pty Ltd Implantable electrode positioning
EP3218046B1 (en) 2014-12-11 2024-04-17 Saluda Medical Pty Ltd Device and computer program for feedback control of neural stimulation
WO2016115596A1 (en) 2015-01-19 2016-07-28 Saluda Medical Pty Ltd Method and device for neural implant communication
US10004896B2 (en) 2015-01-21 2018-06-26 Bluewind Medical Ltd. Anchors and implant devices
US9597521B2 (en) 2015-01-21 2017-03-21 Bluewind Medical Ltd. Transmitting coils for neurostimulation
US9764146B2 (en) 2015-01-21 2017-09-19 Bluewind Medical Ltd. Extracorporeal implant controllers
US9717903B1 (en) 2015-03-17 2017-08-01 Gary Barrett Electronic process to restore, improve and/or strengthen the libido; method to mend the sex drive in males and females
US11167139B2 (en) 2015-03-20 2021-11-09 Medtronic Sg, Llc Method and apparatus for multi modal electrical modulation of pain using composite electromagnetic fields
US10850102B2 (en) 2015-03-20 2020-12-01 Medtronic Sg, Llc Method and apparatus for multimodal electrical modulation of pain
AU2016235457B2 (en) 2015-03-20 2021-01-07 Medtronic Sg, Llc Method and apparatus for multimodal electrical modulation of pain
EP3957356A1 (en) 2015-04-09 2022-02-23 Saluda Medical Pty Limited Electrode to nerve distance estimation
CN107530542B (en) 2015-05-26 2020-10-13 波士顿科学神经调制公司 System for analyzing electrical stimulation and selecting or manipulating activation volume
US10780283B2 (en) 2015-05-26 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
AU2016273415B2 (en) 2015-05-31 2021-07-15 Closed Loop Medical Pty Ltd Monitoring brain neural activity
EP3302692A4 (en) 2015-05-31 2019-01-16 Saluda Medical Pty Limited Brain neurostimulator electrode fitting
CN107613861B (en) 2015-06-01 2021-10-26 闭环医疗私人有限公司 Motor fiber neuromodulation
US9782589B2 (en) 2015-06-10 2017-10-10 Bluewind Medical Ltd. Implantable electrostimulator for improving blood flow
WO2017003946A1 (en) 2015-06-29 2017-01-05 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters based on stimulation target region, effects, or side effects
US10441800B2 (en) 2015-06-29 2019-10-15 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters by targeting and steering
US10071249B2 (en) 2015-10-09 2018-09-11 Boston Scientific Neuromodulation Corporation System and methods for clinical effects mapping for directional stimulation leads
US11318310B1 (en) 2015-10-26 2022-05-03 Nevro Corp. Neuromodulation for altering autonomic functions, and associated systems and methods
US10105540B2 (en) 2015-11-09 2018-10-23 Bluewind Medical Ltd. Optimization of application of current
US9713707B2 (en) 2015-11-12 2017-07-25 Bluewind Medical Ltd. Inhibition of implant migration
CN109310865B (en) 2016-01-25 2022-09-13 内弗洛公司 Electrostimulation treatment of congestive heart failure, and associated systems and methods
US10799701B2 (en) 2016-03-30 2020-10-13 Nevro Corp. Systems and methods for identifying and treating patients with high-frequency electrical signals
UY36936A (en) 2016-03-31 2017-11-30 Medecell S A PROCESS FOR ESTABLISHING AN ELECTRO-STIMULATION PROTOCOL, AND THE RESPECTIVE ELECTRO-STIMULATION PORTABLE EQUIPMENT USING THE REFERRED PROTOCOL
US11191966B2 (en) 2016-04-05 2021-12-07 Saluda Medical Pty Ltd Feedback control of neuromodulation
US10716942B2 (en) 2016-04-25 2020-07-21 Boston Scientific Neuromodulation Corporation System and methods for directional steering of electrical stimulation
US11446504B1 (en) 2016-05-27 2022-09-20 Nevro Corp. High frequency electromagnetic stimulation for modulating cells, including spontaneously active and quiescent cells, and associated systems and methods
JP7278076B2 (en) 2016-06-24 2023-05-19 サルーダ・メディカル・ピーティーワイ・リミテッド Nerve stimulation to reduce artifacts
AU2017281934B2 (en) 2016-06-24 2019-11-14 Boston Scientific Neuromodulation Corporation Systems and methods for visual analytics of clinical effects
US10350404B2 (en) 2016-09-02 2019-07-16 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and directing stimulation of neural elements
US10780282B2 (en) 2016-09-20 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters
JP6828149B2 (en) 2016-10-14 2021-02-10 ボストン サイエンティフィック ニューロモデュレイション コーポレイション Systems and methods for closed-loop determination of stimulation parameter settings for electrical stimulation systems
US10124178B2 (en) 2016-11-23 2018-11-13 Bluewind Medical Ltd. Implant and delivery tool therefor
WO2018128949A1 (en) 2017-01-03 2018-07-12 Boston Scientific Neuromodulation Corporation Systems and methods for selecting mri-compatible stimulation parameters
ES2821752T3 (en) 2017-01-10 2021-04-27 Boston Scient Neuromodulation Corp Systems and procedures for creating stimulation programs based on user-defined areas or volumes
US10625082B2 (en) 2017-03-15 2020-04-21 Boston Scientific Neuromodulation Corporation Visualization of deep brain stimulation efficacy
WO2018187090A1 (en) 2017-04-03 2018-10-11 Boston Scientific Neuromodulation Corporation Systems and methods for estimating a volume of activation using a compressed database of threshold values
US20180353764A1 (en) 2017-06-13 2018-12-13 Bluewind Medical Ltd. Antenna configuration
WO2019014224A1 (en) 2017-07-14 2019-01-17 Boston Scientific Neuromodulation Corporation Systems and methods for estimating clinical effects of electrical stimulation
WO2019036180A1 (en) 2017-08-15 2019-02-21 Boston Scientific Neuromodulation Corporation Systems and methods for controlling electrical stimulation using multiple stimulation fields
US11285329B2 (en) 2018-04-27 2022-03-29 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and programming electrical stimulation
WO2019210202A1 (en) 2018-04-27 2019-10-31 Boston Scientific Neuromodulation Corporation Multi-mode electrical stimulation systems and methods of making and using
US11944820B2 (en) 2018-04-27 2024-04-02 Saluda Medical Pty Ltd Neurostimulation of mixed nerves
EP3883639B1 (en) 2018-11-20 2023-02-22 Nuenerchi, Inc. Electrical stimulation device for applying frequency and peak voltage having inverse relationship
AU2020207940A1 (en) 2019-01-17 2021-08-12 Nevro Corp. Sensory threshold and/or adaptation for neurological therapy screening and/or parameter selection, and associated systems and methods
US11590352B2 (en) 2019-01-29 2023-02-28 Nevro Corp. Ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods
US11918811B2 (en) 2019-05-06 2024-03-05 Medtronic Sg, Llc Method and apparatus for multi modal or multiplexed electrical modulation of pain using composite electromagnetic fields
US11400299B1 (en) 2021-09-14 2022-08-02 Rainbow Medical Ltd. Flexible antenna for stimulator

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT23803B (en) * 1904-04-19 1906-04-10 Carl Kaltschmid Fa Spirit gas burners, especially for flat irons.
FR2336145A1 (en) * 1975-12-23 1977-07-22 Gnudde Michel ELECTROANALGESIA PROCESS WITH CONTACT ELECTRODES
DE2833276A1 (en) * 1977-07-29 1979-02-22 Mo Oblastnoj Nii Akuscherstva DEVICE FOR INFLUENCING THE CENTRAL NERVOUS SYSTEM WITH PULSE CURRENTS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554923A (en) * 1982-08-30 1985-11-26 Batters Robert C Electrical therapeutic assembly and method for reducing pain and edema in a hand
ES8406886A1 (en) * 1982-12-08 1984-08-16 Neurotronic Ltd Electric nerve stimulator to suppress organic pain in human body

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT23803B (en) * 1904-04-19 1906-04-10 Carl Kaltschmid Fa Spirit gas burners, especially for flat irons.
FR2336145A1 (en) * 1975-12-23 1977-07-22 Gnudde Michel ELECTROANALGESIA PROCESS WITH CONTACT ELECTRODES
DE2833276A1 (en) * 1977-07-29 1979-02-22 Mo Oblastnoj Nii Akuscherstva DEVICE FOR INFLUENCING THE CENTRAL NERVOUS SYSTEM WITH PULSE CURRENTS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
L. STINUS ET AL.: "Transcra- nial electrical stimulation with high frequency inter- mittent current (Limoge's) potentiates opiate-induced analgesia: blind studies", PAIN, vol. 42, 23 March 1990 (1990-03-23), pages 351 - 363 *

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8958872B2 (en) 1996-01-08 2015-02-17 Impulse Dynamics, N.V. Electrical muscle controller
US9289618B1 (en) 1996-01-08 2016-03-22 Impulse Dynamics Nv Electrical muscle controller
US9186514B2 (en) 1996-01-08 2015-11-17 Impulse Dynamics Nv Electrical muscle controller
US9713723B2 (en) 1996-01-11 2017-07-25 Impulse Dynamics Nv Signal delivery through the right ventricular septum
EP1007148A1 (en) * 1997-03-10 2000-06-14 Medtronic, Inc. Technique for adjusting the locus of excitation of electrically excitable tissue
EP1007148A4 (en) * 1997-03-10 2003-09-10 Medtronic Inc Technique for adjusting the locus of excitation of electrically excitable tissue
EP1779890A3 (en) * 1997-07-16 2007-07-25 Metacure N.V. Smooth muscle controller
US6947792B2 (en) 1997-07-16 2005-09-20 Impulse Dynamics N.V. Smooth muscle controller
US7120497B2 (en) 1997-07-16 2006-10-10 Metacure Nv Smooth muscle controller
US7006871B1 (en) 1997-07-16 2006-02-28 Metacure N.V. Blood glucose level control
US7221978B2 (en) 1997-07-16 2007-05-22 Metacure Nv Smooth muscle controller
EP0996482A1 (en) * 1997-07-16 2000-05-03 Impulse Dynamics (Israel) Ltd. Smooth muscle controller
EP0996482A4 (en) * 1997-07-16 2004-03-03 Impulse Dynamics Nv Smooth muscle controller
US9265930B2 (en) 1997-07-16 2016-02-23 Metacure Limited Methods and devices for modifying vascular parameters
EP0962234A1 (en) * 1998-06-05 1999-12-08 Pierenkemper GmbH Electrical stimulator for transcutaneous stimulation of nerves and muscles
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US9931503B2 (en) 2003-03-10 2018-04-03 Impulse Dynamics Nv Protein activity modification
US11439815B2 (en) 2003-03-10 2022-09-13 Impulse Dynamics Nv Protein activity modification
US7930037B2 (en) 2003-09-30 2011-04-19 Medtronic, Inc. Field steerable electrical stimulation paddle, lead system, and medical device incorporating the same
US9867980B2 (en) 2003-09-30 2018-01-16 Medtronic, Inc. Field steerable electrical stimulation paddle, lead system, and medical device incorporating the same
US9440080B2 (en) 2004-03-10 2016-09-13 Impulse Dynamics Nv Protein activity modification
US8977353B2 (en) 2004-03-10 2015-03-10 Impulse Dynamics Nv Protein activity modification
US11779768B2 (en) 2004-03-10 2023-10-10 Impulse Dynamics Nv Protein activity modification
US10352948B2 (en) 2004-03-10 2019-07-16 Impulse Dynamics Nv Protein activity modification
US8428735B2 (en) 2004-05-24 2013-04-23 Bioinduction Limited Electrotherapy apparatus
GB2414410A (en) * 2004-05-24 2005-11-30 Bioinduction Ltd Electro-analgesia device applying via body electrodes a biphasic signal having a particular inter-pulse spacing
GB2414410B (en) * 2004-05-24 2006-12-13 Bioinduction Ltd Electrotherapy apparatus
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
US10625074B2 (en) 2013-01-21 2020-04-21 Cala Health, Inc. Devices and methods for controlling tremor
US10850090B2 (en) 2013-01-21 2020-12-01 Cala Health, Inc. Devices and methods for controlling tremor
US10179238B2 (en) 2014-06-02 2019-01-15 Cala Health, Inc. Systems for peripheral nerve stimulation
US10561839B2 (en) 2014-06-02 2020-02-18 Cala Health, Inc. Systems for peripheral nerve stimulation
US9802041B2 (en) 2014-06-02 2017-10-31 Cala Health, Inc. Systems for peripheral nerve stimulation to treat tremor
US10549093B2 (en) 2014-06-02 2020-02-04 Cala Health, Inc. Method for peripheral nerve stimulation
US10905879B2 (en) 2014-06-02 2021-02-02 Cala Health, Inc. Methods for peripheral nerve stimulation
US10960207B2 (en) 2014-06-02 2021-03-30 Cala Health, Inc. Systems for peripheral nerve stimulation
US10173060B2 (en) 2014-06-02 2019-01-08 Cala Health, Inc. Methods for peripheral nerve stimulation
US10765856B2 (en) 2015-06-10 2020-09-08 Cala Health, Inc. Systems and methods for peripheral nerve stimulation to treat tremor with detachable therapy and monitoring units
US11596785B2 (en) 2015-09-23 2023-03-07 Cala Health, Inc. Systems and methods for peripheral nerve stimulation in the finger or hand to treat hand tremors
US11344722B2 (en) 2016-01-21 2022-05-31 Cala Health, Inc. Systems, methods and devices for peripheral neuromodulation for treating diseases related to overactive bladder
US11918806B2 (en) 2016-01-21 2024-03-05 Cala Health, Inc. Systems, methods and devices for peripheral neuromodulation of the leg
US10814130B2 (en) 2016-07-08 2020-10-27 Cala Health, Inc. Dry electrodes for transcutaneous nerve stimulation
US10792495B2 (en) 2016-12-01 2020-10-06 Thimble Bioelectronics, Inc. Neuromodulation device and method for use
US11801383B2 (en) 2016-12-01 2023-10-31 Hinge Health, Inc. Neuromodulation device and method for use
US11331480B2 (en) 2017-04-03 2022-05-17 Cala Health, Inc. Systems, methods and devices for peripheral neuromodulation for treating diseases related to overactive bladder
US11857778B2 (en) 2018-01-17 2024-01-02 Cala Health, Inc. Systems and methods for treating inflammatory bowel disease through peripheral nerve stimulation
US11890468B1 (en) 2019-10-03 2024-02-06 Cala Health, Inc. Neurostimulation systems with event pattern detection and classification

Also Published As

Publication number Publication date
AU5975694A (en) 1994-08-29
GB2290033A (en) 1995-12-13
GB2290033B (en) 1997-01-15
GB9302335D0 (en) 1993-03-24
GB9515702D0 (en) 1995-10-11
US5776170A (en) 1998-07-07

Similar Documents

Publication Publication Date Title
US5776170A (en) Electrotherapeutic apparatus
JP6542926B2 (en) High frequency electric nerve block
US20200230411A1 (en) Systems and methods related to the treatment of back pain
US20220288394A1 (en) Systems and methods for the treatment of pain through neural fiber stimulation
US5002053A (en) Method of and device for inducing locomotion by electrical stimulation of the spinal cord
Kirsch et al. The use of cranial electrotherapy stimulation in the management of chronic pain: a review
Pinter et al. Epidural electrical stimulation of posterior structures of the human lumbosacral cord: 3. Control of spasticity
US5067495A (en) Electro wave therapy
Campbell et al. Peripheral nerve stimulation in the treatment of intractable pain
Eriksson et al. Long term results of peripheral conditioning stimulation as an analgesic measure in chronic pain
US8626302B2 (en) Systems and methods to place one or more leads in muscle for providing electrical stimulation to treat pain
US5851223A (en) Combination non-intrusive analgesic neuroaugmentive system and method triple-modulated gigatens with optional bipolar spike
US6697670B2 (en) Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients
AU2009277037B2 (en) Systems and methods to place one or more leads in muscle for providing electrical stimulation to treat pain
US20050143789A1 (en) Methods and systems for stimulating a peripheral nerve to treat chronic pain
Long Electrical stimulation for the control of pain
CN102176945A (en) Occipital neuromodulation
Saitoh et al. Primary motor cortex stimulation within the central sulcus for treating deafferentation pain
Melzack et al. Acupuncture and transcutaneous electrical nerve stimulation.
CN114555177A (en) System and method for sustained relief of chronic pain
JP2002200179A (en) Instrument for treating chronic pain syndrome, tremor, dementia and related disease and instrument for inducing electrical paralysis using high frequency high strength electric percutaneous stimulation
Singh et al. Transcutaneous spinal stimulation from adults to children: a review
Maiman et al. Spinal cord stimulation for pain
Smith et al. Transcutaneous neural stimulation use in postoperative knee rehabilitation
Shealy et al. Modern medical electricity in the management of pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 08500843

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA